Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Neuroprotection and immunomodulation following intraspinal axotomy of motoneurons by treatment with adult mesenchymal stem cells

Texto completo
Autor(es):
Spejo, A. B. [1] ; Chiarotto, G. B. [1] ; Ferreira, A. D. F. [2] ; Gomes, D. A. [2] ; Ferreira Jr, R. S. ; Barraviera, B. [3] ; Oliveira, A. L. R. [1]
Número total de Autores: 7
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas, SP - Brazil
[2] Univ Fed Minas Gerais, Inst Biol Sci, Dept Biochem & Immunol, Belo Horizonte, MG - Brazil
[3] Ferreira Jr, Jr., R. S., Sao Paulo State Univ UNESP, Ctr Study Venoms & Venomous Anim CEVAP, Botucatu, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: JOURNAL OF NEUROINFLAMMATION; v. 15, AUG 14 2018.
Citações Web of Science: 6
Resumo

Background: Treatment of spinal cord injury is dependent on neuronal survival, appropriate synaptic circuit preservation, and inflammatory environment management. In this sense, mesenchymal stem cell (MSC) therapy is a promising tool that can reduce glial reaction and provide trophic factors to lesioned neurons. Methods: Lewis adult female rats were submitted to a unilateral ventral funiculus cut at the spinal levels L4, L5, and L6. The animals were divided into the following groups: IA (intramedullary axotomy), IA + DMEM (Dulbecco's modified Eagle's medium), IA + FS (fibrin sealant), IA + MSC (106 cells), and IA + FS + MSC (106 cells). Seven days after injury, qPCR (n = 5) was performed to assess gene expression of VEGF, BDNF, iNOS2, arginase-1, TNF-alpha, IL-1 beta, IL-6, IL-10, IL-4, IL-13, and TGF-beta. The cellular infiltrate at the lesion site was analyzed by hematoxylin-eosin (HE) staining and immunohistochemistry (IH) for Iba1 (microglia and macrophage marker) and arginase-1. Fourteen days after injury, spinal alpha motor neurons (MNs), evidenced by Nissl staining (n = 5), were counted. For the analysis of astrogliosis in spinal lamina IX and synaptic detachment around lesioned motor neurons (GAP-43-positive cells), anti-GFAP and anti-synaptophysin immunohistochemistry (n = 5) was performed, respectively. Twenty-eight days after IA, the gait of the animals was evaluated by the walking track test (CatWalk; n = 7). Results: The site of injury displayed strong monocyte infiltration, containing arginase-1-expressing macrophages. The FS-treated group showed upregulation of iNOS2, arginase-1, proinflammatory cytokine (TNF-alpha and IL-1 beta), and antiinflammatory cytokine (IL-10, IL-4, and IL-13) expression. Thus, FS enhanced early macrophage recruitment and proinflammatory cytokine expression, which accelerated inflammation. Rats treated with MSCs displayed high BDNF-positive immunolabeling, suggesting local delivery of this neurotrophin to lesioned motoneurons. This BDNF expression may have contributed to the increased neuronal survival and synapse preservation and decreased astrogliosis observed 14 days after injury. At 28 days after lesion, gait recovery was significantly improved in MSC-treated animals compared to that in the other groups. Conclusions: Overall, the present data demonstrate that MSC therapy is neuroprotective and, when associated with a FS, shifts the immune response to a proinflammatory profile. (AU)

Processo FAPESP: 14/06892-3 - Utilização de células tronco mesenquimais na interface do sistema nervoso central e periférico: reparo de lesões proximais
Beneficiário:Alexandre Leite Rodrigues de Oliveira
Modalidade de apoio: Auxílio à Pesquisa - Temático
Processo FAPESP: 12/22750-9 - Emprego de selante de fibrina combinado com células tronco mesenquimais para o reparo de lesão no funículo anterior: efeitos sobre a inflamação, neuroproteção e regeneração axonal.
Beneficiário:Aline Barroso Spejo
Modalidade de apoio: Bolsas no Brasil - Doutorado
Processo FAPESP: 13/16168-8 - Emprego de riluzole, tempol e células tronco mesenquimais no tratamento da esclerose lateral amiotrófica em camundongos SOD1 G93A
Beneficiário:Gabriela Bortolança Chiarotto
Modalidade de apoio: Bolsas no Brasil - Doutorado